From:  Therapeutic targets for metabolic dysfunction-associated steatotic liver disease and their roles in hepatocellular carcinoma

Related drugs targeting PPARα

PPARα agonistsAliasMolecular formulaChemical structureR & D stageReferences
FenofibrateFNFC20H21ClO4Approval to market[34]
GemfibrozilGEM, CI-719C15H22O3Approval to market[37]
BezafibrateLO-44C19H20ClNO4Approval to market[38]
PemafibrateJAN, K-877, K-877-FL, K-877-ER, K-877-BCC28H30N2O6Approval to market[39]
Return to article view